Fig. 1.

Binding and blocking profiles of IBI101. a Cell-based binding assay was conducted for IBI101, pogalizumab (POGA) and OX40L using CHO-S/hOX40 stable cell line and anti-human Fc-PE secondary antibody. b Cell-based blocking assay was conducted for IBI101, POGA and OX40L using CHO-S/hOX40 stable cell line and biotin-OX40L with human Fc. After incubation and washing, biotin-OX40L-human-Fc was detected by Streptavidin R-Phycoerythrin Conjugate (SAPE). c Primary cell-based binding assay for IBI101, POGA and OX40L using activated human CD4+ T cells and anti-human Fc-PE secondary antibody. d Primary cell-based binding assay was conducted for IBI101, POGA and OX40L using activated cynomolgus monkey PBMCs cells and anti-human Fc-PE secondary antibody. All the data are representative of at least three independent experiments or different donors